Ophidion CNS Carrier Technology

The blood-brain barrier blocks more than 95 percent of systemically administered drugs from reaching the brain, creating a major obstacle for CNS drug development.

Ophidion’s CNS Carrier Technology (OCCT) overcomes this barrier using a Trojan horse approach that leverages endogenous receptor-mediated transport to deliver intravenously or subcutaneously administered therapeutics into the brain. The platform supports a broad range of cargo, including peptides, gene-silencing agents such as siRNAs and ASOs, antibodies, and other macromolecules.